Latitude Pharma Provides 505b2 Licensing Opportunity Through Formulation Development Service

San Diego, CA (November 15, 2017) – The internal product development activities of Latitude Pharma pays attention to activities that address zones of unattended medical needs through the right formulation development service. The activities include taking the familiar drugs and making them considerably safer. Not just safer, they are made easier to use and more stable and they also come up with new intellectual property.

Being a Formulation development contract research organization, the company makes sure that the re-formulations become eligible for the 505b2 licensing opportunity. This, in turn, helps the licensor to save a considerable amount of time and cost when they reach FDA for approval of their drugs.

Latitude offers the 505(b)(2) licensing opportunity for a wide range of drug products and some of the include Intra-V, Opti-V, Rescue-G, PumpaGon, PAC-E, DOCE-E, Nano-K, Nano-A and 24H Tramadol. Further, with the GLP formulation expertise, Latitude has developed novel formulations of the already familiar drugs in new dose formats.

About Latitude Pharmaceuticals Inc.:
Right from the inception in the year 2003, Latitude Pharma has performed more than 750 formulation development projects. The company has offered this service for more than 200 of their client organization. This helped the company to develop a worldwide reputation for their creative approaches.

For more information, please visit


This press release has been viewed 104 times on PR Buzz.